BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 17317716)

  • 1. Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis.
    Illei GG; Yarboro CH; Kuroiwa T; Schlimgen R; Austin HA; Tisdale JF; Chitkara P; Fleisher T; Klippel JH; Balow JE; Boumpas DT
    Rheumatology (Oxford); 2007 Jun; 46(6):952-6. PubMed ID: 17317716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy.
    Boumpas DT; Tassiulas IO; Fleisher TA; Vaughan E; Piscitelli S; Kim Y; Pucino F; Balow JE; Austin HA
    Clin Nephrol; 1999 Aug; 52(2):67-75. PubMed ID: 10480216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
    Petrović R; Stojanović R; Novicić-Sasić D; Dimitrijević J; Pavlović S; Stojković D; Palić-Obradović D; Stevanović G; Prodanović S
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of intravenous pulse cyclophosphamide in the treatment of severe lupus nephritis in children.
    Tangnararatchakit K; Tapaneya-Olarn C; Tapaneya-Olarn W
    J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S104-10. PubMed ID: 10730528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; de Ramon Garrido E; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive treatment of the glomerulonephritis of systemic lupus.
    Faedda R; Palomba D; Satta A; Pirisi M; Tanda F; Bartoli E
    Clin Nephrol; 1995 Dec; 44(6):367-75. PubMed ID: 8719548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis.
    Davis JC; Fessler BJ; Tassiulas IO; McInnes IB; Yarboro CH; Pillemer S; Wilder R; Fleisher TA; Klippel JH; Boumpas DT
    J Rheumatol; 1998 Sep; 25(9):1694-704. PubMed ID: 9733448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study.
    Valeri A; Radhakrishnan J; Estes D; D'Agati V; Kopelman R; Pernis A; Flis R; Pirani C; Appel GB
    Clin Nephrol; 1994 Aug; 42(2):71-8. PubMed ID: 7955581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
    Sacchi S; Pozzi S; Marcheselli R; Federico M; Tucci A; Merli F; Orsucci L; Liberati M; Vallisa D; Brugiatelli M;
    Cancer; 2007 Jul; 110(1):121-8. PubMed ID: 17503433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years.
    Moroni G; Doria A; Mosca M; Alberighi OD; Ferraccioli G; Todesco S; Manno C; Altieri P; Ferrara R; Greco S; Ponticelli C
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):925-32. PubMed ID: 17699309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study.
    Wang HY; Cui TG; Hou FF; Ni ZH; Chen XM; Lu FM; Xu FF; Yu XQ; Zhang FS; Zhao XZ; Zhao MH; Wang GB; Qian JQ; Cai GY; Zhu TY; Wang YH; Jiang ZP; Li YN; Mei CL; Zou WZ;
    Lupus; 2008 Jul; 17(7):638-44. PubMed ID: 18625636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis.
    Szeto CC; Kwan BC; Lai FM; Tam LS; Li EK; Chow KM; Gang W; Li PK
    Rheumatology (Oxford); 2008 Nov; 47(11):1678-81. PubMed ID: 18753192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulse cyclophospamide in severe lupus nephritis: Southern Indian experience.
    Das U; Dakshina Murty KV; Prasad N; Prayag A
    Saudi J Kidney Dis Transpl; 2010 Mar; 21(2):372-8. PubMed ID: 20228536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
    Gunnarsson I; Sundelin B; Jónsdóttir T; Jacobson SH; Henriksson EW; van Vollenhoven RF
    Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of enteric-coated mycophenolate sodium in patients with active lupus nephritis.
    Mak SK; Lo KY; Lo MW; Chan SF; Tong GM; Wong PN; Wong AK
    Nephrology (Carlton); 2008 Jun; 13(4):331-6. PubMed ID: 18476916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
    Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
    Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.
    Grootscholten C; Bajema IM; Florquin S; Steenbergen EJ; Peutz-Kootstra CJ; Goldschmeding R; Bijl M; Hagen EC; Van Houwelingen HC; Derksen RH; Berden JH;
    Arthritis Rheum; 2007 Mar; 56(3):924-37. PubMed ID: 17328070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?
    Li EK; Tam LS; Zhu TY; Li M; Kwok CL; Li TK; Leung YY; Wong KC; Szeto CC
    Rheumatology (Oxford); 2009 Aug; 48(8):892-8. PubMed ID: 19478041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.